Kimyrsa FDA Approval History
Last updated by Judith Stewart, BPharm on April 1, 2021.
Kimyrsa (oritavancin) is a lipoglycopeptide antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSI) caused by designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
- Kimyrsa is a long-acting, single-dose antibiotic administered by intravenous infusion over 1 hour.
- Kimyrsa is the second oritavancin product to be approved by the FDA after the approval of Orbactiv in 2014. Orbactiv is administered as a single-dose intravenous infusion over 3 hours.
- Common adverse reactions in people treated with oritavancin include headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
Development Timeline for Kimyrsa
|Mar 15, 2021||Approval FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.